Pacira pain drug succeeds in late-stage trial
Feb 27 (Reuters) - Pacira Pharmaceuticals Inc said a late-stage trial testing its drug Exparel for a wider use showed the treatment significantly reduced pain compared to placebo in knee surgery patients.
Exparel is already approved for use in managing post-surgical pain when administered directly at the site of the pain. The latest trial was testing Exparel's efficacy when applied to a major nerve adjacent to the site of the surgery, thereby blocking any sensation until the nerve endings.
A late-stage trial testing the drug, Exparel, showed that patients taking the medicine experienced significant reduction in pain over 72 hours.
Trending On Reuters
We are living longer but not creating financial plans to keep pace. Advisers give tips on how to make sure you don’t outlive your money. Video